Compare Stocks: IPHA, PRME, WVE, and SVA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IPHA Innate Pharma	$1.43 -3.4%	$1.91	$1.17 ▼ $2.71	$159.76M	0.72	47,138 shs	8,028 shs
PRME Prime Medicine	$3.47 -3.9%	$3.34	$2.67 ▼ $6.30	$629.38M	2.37	5.11 million shs	4.39 million shs
SVA Sinovac Biotech	$6.47	$6.47	$5.73 ▼ $8.75	$644.66M	0.76	N/A	N/A
WVE WAVE Life Sciences	$3.13 -1.9%	$4.44	$3.04 ▼ $21.73	$617.32M	-1.43	3.36 million shs	3.28 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IPHA Innate Pharma	0.00%	-11.73%	-25.13%	-18.29%	-32.23%
PRME Prime Medicine	0.00%	-13.03%	+10.51%	+10.86%	-45.53%
SVA Sinovac Biotech	0.00%	0.00%	0.00%	0.00%	0.00%
WVE WAVE Life Sciences	0.00%	-9.54%	-29.50%	-46.22%	-61.31%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IPHA Innate Pharma	$1.43 -3.4%	$1.91	$1.17 ▼ $2.71	$159.76M	0.72	47,138 shs	8,028 shs
PRME Prime Medicine	$3.47 -3.9%	$3.34	$2.67 ▼ $6.30	$629.38M	2.37	5.11 million shs	4.39 million shs
SVA Sinovac Biotech	$6.47	$6.47	$5.73 ▼ $8.75	$644.66M	0.76	N/A	N/A
WVE WAVE Life Sciences	$3.13 -1.9%	$4.44	$3.04 ▼ $21.73	$617.32M	-1.43	3.36 million shs	3.28 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IPHA Innate Pharma	0.00%	-11.73%	-25.13%	-18.29%	-32.23%
PRME Prime Medicine	0.00%	-13.03%	+10.51%	+10.86%	-45.53%
SVA Sinovac Biotech	0.00%	0.00%	0.00%	0.00%	0.00%
WVE WAVE Life Sciences	0.00%	-9.54%	-29.50%	-46.22%	-61.31%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IPHA Innate Pharma	2.67	Moderate Buy	$6.67	366.20% Upside
PRME Prime Medicine	2.90	Moderate Buy	$7.47	115.34% Upside
SVA Sinovac Biotech	3.00	Buy	$1.00	-84.54% Downside
WVE WAVE Life Sciences	2.85	Moderate Buy	$21.53	587.84% Upside

Current Analyst Ratings Breakdown

Latest IPHA, PRME, WVE, and SVA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/16/2026	WVE WAVE Life Sciences	William Blair Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform
10/15/2026	WVE WAVE Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	WVE WAVE Life Sciences	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$11.00
10/14/2026	WVE WAVE Life Sciences	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
10/2/2026	WVE WAVE Life Sciences	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$13.00
10/2/2026	WVE WAVE Life Sciences	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/1/2026	WVE WAVE Life Sciences	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$10.00
9/28/2026	PRME Prime Medicine	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Outperform
9/25/2026	PRME Prime Medicine	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Outperform
9/25/2026	PRME Prime Medicine	Chardan Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$7.00
9/23/2026	WVE WAVE Life Sciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight ➝ Neutral

(Data available from 10/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IPHA Innate Pharma	$4.23M	37.76	N/A	N/A	($0.26) per share	-5.50
PRME Prime Medicine	$4.63M	135.94	N/A	N/A	$0.67 per share	5.18
SVA Sinovac Biotech	$386.01M	1.67	$0.54 per share	11.89	$89.01 per share	0.07
WVE WAVE Life Sciences	$65.37M	9.44	N/A	N/A	$3.10 per share	1.01

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IPHA Innate Pharma	-$55.64M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PRME Prime Medicine	-$201.14M	-$1.06	N/A	N/A	N/A	-4,613.11%	-188.27%	-59.11%	N/A
SVA Sinovac Biotech	-$59.68M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
WVE WAVE Life Sciences	-$204.38M	-$1.09	N/A	N/A	N/A	-309.73%	-50.36%	-40.06%	11/9/2026 (Estimated)

Latest IPHA, PRME, WVE, and SVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q3 2026	WVE WAVE Life Sciences	-$0.33	N/A	N/A	N/A	$4.51 million	N/A
8/6/2026	Q2 2026	PRME Prime Medicine	-$0.24	-$0.24	N/A	-$0.24	$4.40 million	$1.15 million
7/30/2026	Q2 2026	WVE WAVE Life Sciences	-$0.2998	-$0.34	-$0.0403	-$0.34	$7.45 million	$2.27 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IPHA Innate Pharma	N/A	N/A	N/A	N/A	N/A
PRME Prime Medicine	N/A	N/A	N/A	N/A	N/A
SVA Sinovac Biotech	N/A	N/A	N/A	N/A	N/A
WVE WAVE Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IPHA Innate Pharma	N/A	0.60	N/A
PRME Prime Medicine	N/A	3.05	3.05
SVA Sinovac Biotech	0.04	6.07	5.97
WVE WAVE Life Sciences	N/A	9.99	9.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IPHA Innate Pharma	0.16%
PRME Prime Medicine	70.37%
SVA Sinovac Biotech	N/A
WVE WAVE Life Sciences	89.73%

Insider Ownership

Company	Insider Ownership
IPHA Innate Pharma	31.89%
PRME Prime Medicine	16.04%
SVA Sinovac Biotech	12.79%
WVE WAVE Life Sciences	24.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IPHA Innate Pharma	163	111.72 million	76.09 million	Not Optionable
PRME Prime Medicine	146	181.38 million	152.28 million	N/A
SVA Sinovac Biotech	3,008	99.64 million	86.89 million	Optionable
WVE WAVE Life Sciences	317	197.23 million	149.30 million	Optionable

IPHA, PRME, WVE, and SVA Headlines

Recent News About These Companies

Wave Life Sciences (WVE) Stock Fair Value Moves Lower As Analysts Cut Growth Views

October 17 at 3:02 PM | finance.yahoo.com

WAVE Life Sciences (NASDAQ:WVE) Stock Bumped Up to Strong-Buy by UBS Group

October 17 at 12:35 PM | marketbeat.com

Wave Life Sciences Inc.

October 16 at 12:24 PM | money.usnews.com

UBS starts coverage of Wave Life Sciences stock with USD 11 target

October 15 at 9:10 AM | ad-hoc-news.deA

Wave Life Sciences to Present at Chardan’s 10th Annual Healthcare Conference

October 13, 2026 | markets.businessinsider.com

Wave Life Sciences to Present at Chardan's 10th Annual Healthcare Conference

October 13, 2026 | globenewswire.com

WAVE Life Sciences (NASDAQ:WVE) Reaches New 52-Week Low - Should You Sell?

October 12, 2026 | americanbankingnews.com

WAVE Life Sciences (NASDAQ:WVE) Sets New 1-Year Low - Here's Why

October 12, 2026 | marketbeat.com

Heidi L. Wagner Awarded 10,700 RSUs and 64,000 Stock Options at Wave Life Sciences

October 9, 2026 | kalkinemedia.comK

WAVE Life Sciences (NASDAQ:WVE) Sets New 52-Week Low - Time to Sell?

October 6, 2026 | marketbeat.com

Wave Life Sciences stock gets FDA backing for WVE-006 path

October 6, 2026 | ad-hoc-news.deA

Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (WVE), Liquidia Technologies (LQDA) and Abbott Laboratories (ABT)

October 3, 2026 | theglobeandmail.com

Analysts Are Bullish on Top Healthcare Stocks: Johnson & Johnson (JNJ), Wave Life Sciences (WVE)

October 3, 2026 | theglobeandmail.com

Wave Life Sciences gets FDA backing for WVE-006 registrational trial

October 1, 2026 | streetinsider.com

Wave Life Sciences Says FDA Feedback Supports Registrational Pathway for WVE-006

October 1, 2026 | finance.yahoo.com

Wave Gains FDA Support For WVE-006 Registrational Pathway In AATD

October 1, 2026 | rttnews.com

Wave Life Sciences Says FDA Feedback Supports Genetic Disease Treatment

October 1, 2026 | marketwatch.com

Wave Life jumps as FDA backs registrational plans for AATD therapy

October 1, 2026 | seekingalpha.com

WAVE Life Sciences (NASDAQ:WVE) Shares Up 9.3% - Here's Why

October 1, 2026 | marketbeat.com

LADENBURG THALM/SH SH Initiates Coverage on WAVE Life Sciences (NASDAQ:WVE)

October 1, 2026 | marketbeat.com

Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATD

October 1, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPHA, PRME, WVE, and SVA Company Descriptions

Innate Pharma NASDAQ:IPHA

$1.43 -0.05 (-3.38%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$1.44 +0.01 (+0.70%)

As of 10/16/2026 07:00 PM Eastern

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

Prime Medicine NASDAQ:PRME

$3.47 -0.14 (-3.88%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$3.45 -0.02 (-0.69%)

As of 10/16/2026 07:49 PM Eastern

We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology. Genetic mutations implicated in disease are diverse and can range from errors of a single base, known as point mutations, to errors that extend beyond a single base, such as insertions, deletions, duplications, or combinations thereof. We believe the ability to alter the human genome at the foundational level may confer the greatest therapeutic impact on human disease. Gene editing, including platforms such as Prime Editing, is a novel technology that is not yet clinically validated for human therapeutic use. Over the last decade, the field of genetic medicine has evolved tremendously, with groundbreaking advances in gene therapy, cell therapy, RNA therapy, and, more recently, gene editing. These technologies represent dramatic advancements for genetic therapies, but lack the versatility to precisely and efficiently correct the diverse range of mutations or DNA alterations implicated in disease. Prime Medicine was co-founded by a world-renowned leader in the field of gene editing, David Liu, Ph.D. Dr. Liu was joined as co-founder by Andrew Anzalone, M.D., Ph.D., who conceived of and developed Prime Editing technology. Drawn by the promise of Prime Editing’s ability to transform the field of gene editing, we have assembled a diverse team that has grown to more than 150 people as of September 30, 2022. There are no current plans for Dr. Liu to be an officer or director of our company following this offering. He is expected to continue to provide consulting services to us pursuant to a consulting agreement, which has a current term that runs through September 2025 and accommodates a previous commitment with respect to Beam Therapeutics Inc., which could result in or may create the appearance of a conflict of interest. He is also expected to retain his position and affiliation with the Broad Institute, Inc., Howard Hughes Medical Institute and Harvard University. On September 20, 2022, we achieved a major milestone as the United States Patent and Trademark Office, or the USPTO, issued U.S. Patent 11,447,770, or the ‘770 Patent, covering methods of using Prime Editors. The Broad Institute, Inc., or Broad Institute, prepared, filed and prosecuted the ‘770 Patent. While Broad Institute is the owner of the ‘770 Patent, it is exclusively licensed to us under the terms of the license agreement with Broad Institute. The ‘770 Patent is the first issued Prime Editing patent in our licensed patent portfolio and we believe it will be instrumental in protecting our Prime Editing platform and pipeline of gene editing programs. We believe our in-licensed and company-owned Prime Editing technology has transformative potential that could change the course of how disease is treated and overcome the challenges associated with current genetic therapies. We in-license our Prime Editing technology pursuant to a license agreement with Broad Institute. In addition, the license agreement grants us certain rights and licenses under certain patent rights Broad Institute owns or controls, including a license to the ‘770 Patent, which covers Prime Editing technology and expires in 2040. The licenses are limited to the field of prevention or treatment of human disease, and most licenses granted to us under the license agreement are further limited to the prevention or treatment of human disease by editing (including modifying or converting) or targeting DNA ex vivo, in vivo, or through xeno transplantation methods, which we refer to as the Prime Broad Field. We were incorporated under the laws of the State of Delaware in September 2019 under the name Prime Medicine, Inc. Our principal executive offices are located at 21 Erie Street, Cambridge, MA.

Sinovac Biotech NASDAQ:SVA

$6.47 0.00 (0.00%)

As of 10/16/2026

Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.

WAVE Life Sciences NASDAQ:WVE

$3.13 -0.06 (-1.88%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$3.12 -0.01 (-0.48%)

As of 10/16/2026 07:30 PM Eastern

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IPHA, PRME, WVE, and SVA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IPHA, PRME, WVE, and SVA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IPHA, PRME, WVE, and SVA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPHA, PRME, WVE, and SVA Company Descriptions

Innate Pharma NASDAQ:IPHA

Prime Medicine NASDAQ:PRME

Sinovac Biotech NASDAQ:SVA

WAVE Life Sciences NASDAQ:WVE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IPHA, PRME, WVE, and SVA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IPHA, PRME, WVE, and SVA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IPHA, PRME, WVE, and SVA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPHA, PRME, WVE, and SVA Company Descriptions

Innate Pharma NASDAQ:IPHA

Prime Medicine NASDAQ:PRME

Sinovac Biotech NASDAQ:SVA

WAVE Life Sciences NASDAQ:WVE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools